




RealRate

PHARMACEUTICAL 2017

Immagine Biotherapeutics CORP
Rank 155 of 308



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Immagine Biotherapeutics CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Immagine Biotherapeutics CORP compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 61% points. The greatest weakness of Immagine Biotherapeutics CORP is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 46% points.

The company's Economic Capital Ratio, given in the ranking table, is 252%, being 7.3% points above the market average of 245%.

Input Variable	Value in 1000 USD
Assets, Current	205
Cost of Goods Sold	0
Intangible Assets	5.9
Liabilities, Current	56
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	55
Other Liabilities	0
Other Net Income	0
Other Revenues	0
Property and Equipment	32
Research and Development	62
Selling, General and Administrative Expense	99

Output Variable	Value in 1000 USD
Assets	243
Liabilities	56
Expenses	216
Revenues	0
Stockholders Equity	187
Net Income	-216
Comprehensive Net Income	-216
BaseVar	258
ECR before LimitedLiability	128%
Economic Capital Ratio	252%